KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Common Equity (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of Common Equity data on record, last reported at $1.6 billion in Q4 2025.

  • For Q4 2025, Common Equity rose 0.63% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, up 0.63%, while the annual FY2025 figure was $1.6 billion, 0.63% up from the prior year.
  • Common Equity reached $1.6 billion in Q4 2025 per IDXX's latest filing, up from $1.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.6 billion in Q3 2024 and bottomed at $457.0 million in Q2 2022.
  • Average Common Equity over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2023.
  • Peak YoY movement for Common Equity: soared 551.0% in 2021, then crashed 38.92% in 2022.
  • A 5-year view of Common Equity shows it stood at $690.0 million in 2021, then fell by 11.78% to $608.7 million in 2022, then surged by 143.87% to $1.5 billion in 2023, then rose by 7.46% to $1.6 billion in 2024, then rose by 0.63% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.5 billion in Q2 2025.